Synthetic Biologics CEO outlines development plans for lead assets SYN-004 and SYN-010

Synthetic Biologics CEO Jeffrey Riley outlines to Pharma Intelligence Senior Editor Sten Stovall how the clinical stage developer of therapeutics to protect the gut microbiome while targeting pathogen-specific diseases plans to advance its pipeline, which currently contains two lead candidates in Phase II. The most advanced, SYN-004, is designed to protect the gut microbiome from the effects of certain commonly used intravenous beta-lactam antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD). SYN-010 aims to reduce the impact of methane producing organisms in the gut.

Interviewer: Sten Stovall – Senior Editor, Pharma Intelligence, In Vivo/Pink Sheet/Scrip

Interviewee: Jeffrey Riley – CEO, Synthetic Biologics, Inc.